Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
HighCape Capital is a growth equity fund founded in 2013 and based in the United States. The firm focuses on assisting innovative Life Sciences companies in transitioning from the initial stages of their business cycle into successful, thriving organizations. The team comprises experienced executives with backgrounds in founding, financing, leading, growing, and exiting various Life Sciences companies across multiple industry segments.
As of now, HighCape Capital manages an $80 million growth equity fund and has invested in six companies. The firm has a target portfolio of 6 to 8 companies per fund, indicating a selective investment strategy. HighCape Capital has established itself as a notable player in the Life Sciences sector, particularly in areas such as Connected Health, Medical Devices, and Biotechnology. The firm is a member of BioCT, a Connecticut-based life sciences network.
HighCape Capital invests primarily in the Life Sciences sector, with a specific focus on Connected Health, Medical Devices/Tools, and Biotechnology. The firm targets investments across various stages, including pre-seed, seed, seed-plus, series A, and growth equity. HighCape Capital employs a hands-on approach to partner with management teams, enhancing their commercial and operational strategies. This active involvement is designed to facilitate growth and successful exits for portfolio companies.
The firm seeks innovative Life Sciences companies at early revenue or product launch stages. HighCape Capital looks for superior products with a clear commercialization path and measurable value to the healthcare system. Their investment strategy emphasizes collaboration with management teams to refine operational strategies and drive market success.
HighCape Capital has invested in several notable companies within the Life Sciences sector, including:
These investments reflect HighCape Capital's commitment to supporting innovative companies that are poised for growth and success in the Life Sciences field.
Kevin Rakin - Co-founder and Partner. Rakin has extensive experience in the Life Sciences sector, having led multiple successful investments and exits.
Matt Zuga - Co-founder. Zuga brings a wealth of knowledge in venture capital and operational management within the Life Sciences industry.
Jennifer Barretta - Operating Partner. Barretta has a strong background in healthcare investments and operational strategy.
Ranjit Bindra, MD, PhD - Operating Partner. Bindra has expertise in medical devices and biotechnology, contributing to HighCape's investment decisions.
Charles Hart, PhD - Operating Partner. Hart specializes in biotech and has a track record of successful company growth and exits.
To pitch to HighCape Capital, founders should visit their website at highcape.com. It is recommended to include a comprehensive pitch deck that outlines the business model, market opportunity, and financial projections. While specific response time expectations are not provided, founders should anticipate a thorough review process.
In 2024, HighCape Capital's portfolio company, Modifi Biosciences, was acquired by Merck, marking a significant exit for the firm. Additionally, HighCape Capital participated in a $6.4 million seed round for Modifi Biosciences, focusing on brain cancer therapies.
In 2021, HighCape Capital completed a business combination with Quantum-Si through a SPAC, valuing the deal at over $1 billion. Quantum-Si focuses on next-generation proteomics using semiconductor chips and is now publicly traded on NASDAQ under the ticker QSI.
HighCape Capital also filed for a $200 million SPAC IPO in March 2021, indicating its ongoing commitment to expanding its investment capabilities in the Life Sciences sector.
What are HighCape Capital's investment criteria?
HighCape Capital invests in innovative Life Sciences companies, particularly in Connected Health, Medical Devices, and Biotechnology. They focus on early revenue or product launch stages and look for companies with superior products and a clear path to commercialization.
How can I apply or pitch to HighCape Capital?
Founders can pitch to HighCape Capital through their website at highcape.com. It is advisable to include a detailed business plan and financial projections in the pitch deck.
What makes HighCape Capital different from other investors?
HighCape Capital distinguishes itself through its hands-on approach, actively partnering with management teams to enhance their commercial and operational strategies. Their team comprises experienced executives with a strong background in the Life Sciences sector.
What is the geographic scope of HighCape Capital's investments?
The firm primarily invests in companies based in the United States, focusing on the Life Sciences sector.
What is the typical check size for investments?
HighCape Capital invests across various stages, including pre-seed, seed, seed-plus, series A, and growth equity, although specific check sizes are not disclosed.
What is HighCape Capital's post-investment involvement like?
HighCape Capital takes an active role in supporting its portfolio companies, working closely with management teams to refine their strategies and facilitate growth.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.